Cited by 1,506Atrial Fibrillation Management and OutcomesCardiac Valve Diseases and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Eikelboom, John W., Connolly, Stuart J., Brueckmann, Martina, Granger, Christopher B., Kappetein, Arie P., Mack, Michael J., Blatchford, Jon, Devenny, Kevin, Friedman, Jeffrey, Guiver, Kelly, Harper, Ruth, Khder, Yasser, Lobmeyer, Maximilian T., Maas, Hugo, Voigt, Jens-Uwe, Simoons, Maarten L., Van de Werf, Frans·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1300615

Open this paper in CoChat — free account

Abstract

BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level of dabigatran. RESULTS: The trial was terminated prematurely after the enrollment of 252 patients because of an excess of thromboembolic and bleeding events among patients in the dabigatran group. In the as-treated analysis, dose adjustment or discontinuation of dabigatran was required in 52 of 162 patients (32%). Ischemic or unspecified stroke occurred in 9 patients (5%) in the dabigatran group and in no patients in the warfarin group; major bleeding occurred in 7 patients (4%) and 2 patients (2%), respectively. All patients with major bleeding had pericardial bleeding. CONCLUSIONS: The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1300615

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
Schulman, S., Angerås, U., Bergqvist, D., ERIKSSON, B., Lassen, M. R., & FISHER, W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,761
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Oral Anticoagulant Therapy
Ageno, W., Gallus, A. S., Wittkowsky, A. K., Crowther, M. A., Hylek, E. M., & Palareti, G. (2012) · CHEST Journal · doi:10.1378/chest.11-2292 · Cited by 1,583
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium
Leon, M. B., Piazza, N., Nikolsky, E., Blackstone, E. H., Cutlip, D. E., Kappetein, A. P., Krucoff, M. W., Mack, M. J., Mehran, R., Miller, D. C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq406 · Cited by 1,217
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
Watson, T., Shantsila, E., & Lip, G. Y. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60040-4 · Cited by 1,124

Flagged first, then by citations

Show all 27 references

1 of the 27 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Dewanjee MK, 1999, J Heart Valve Dis, 8, 324

Sorted by citations

Items 901–1,000 of 1,000

Direkt orális antikoagulánst szedő betegek sürgősségi ellátása: gyakorlati szempontok
Zátroch, I., & Fazakas, J. (2025) · Orvosi Hetilap · doi:10.1556/650.2025.33299 · Cited by 3
Eficacia y seguridad del tratamiento anticoagulante oral con antagonistas de vitamina K en pacientes con prótesis valvulares cardíacas
Marín, A., Neira, V., Aizman, A., Alejandro Paredes, C., Soledad Palma, R., Ruiz, M. C. G., Revello, J., Zvaighaft, S., Cea, C., & Corbalan, R. L. (2014) · Revista chilena de cardiología · doi:10.4067/s0718-85602014000100003 · Cited by 3
Novel anticoagulants in patients with mechanical heart valves
Stewart, R. (2014) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2013-101624 · Cited by 3
Anticoagulant therapy in atrial fibrillation
Riva, N., Xuereb, C. B., & Ageno, W. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000212 · Cited by 3
Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1
Akao, M., Beyer‐Westendorf, J., Goto, S., & Peterson, E. D. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv037 · Cited by 3
Use of Direct Oral Anticoagulants in Special Populations
Li, A., Lópes, R. D., & Garcia, D. A. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.003 · Cited by 3
“Finally, edoxaban is contraindicated in patients with an eCrCl of greater than 95 mL/min because a post hoc analysis of the ENGAGEAF-TIMI 48 study showed that this subgroup of patientsmay have higher rates of ischemic stroke or systemic embolism with edoxaban 60 mg compared with VKA.45 In summary, the DOACs (as a clas…”
BackgroundInfluential
Vitamin-K-Antagonisten
Rafflenbeul, E., & Müller‐Ehmsen, J. (2017) · Der Internist · doi:10.1007/s00108-016-0168-x · Cited by 3
Double Whammy: Pigment Nephropathy and Warfarin-related Nephropathy As Aetiology for Acute Kidney Injury in a Patient With Mechanical Heart Valves
Conjeevaram, A., Lohia, P., Ravishankar, G. S., & Vankalakunti, M. (2019) · The Open Urology & Nephrology Journal · doi:10.2174/1874303x01912010041 · Cited by 3
Warfarin Reinitiation After Intracranial Hemorrhage: A Case Series of Heart Valve Patients
Wan, A. W., Butcher, K., Hodgson, M., Schultz, K., & Bungard, T. J. (2019) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2019.331 · Cited by 3
Targeting multiple enzymes in vitamin K metabolism for anticoagulation
Li, W. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15212 · Cited by 3
The Safety and Efficacy of Low-Molecular-Weight Heparin in Pregnant Women With Rheumatic Heart Disease and Valves Replacement
Alghamdi, N., Alqahani, S., Allehyani, L., Alosaimi, H., Almutairi, W., Alobaid, S., Albackr, H. B., Aldakhil, L., Alotaibi, G., & Alqahtani, F. H. (2022) · Cureus · doi:10.7759/cureus.23052 · Cited by 3
Warfarin
Hadlock, G. C., Burnett, A., & Nutescu, E. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_2 · Cited by 3
Aortic valve disease
Linefsky, J. P., & Otto, C. M. (2014) · Medicine · doi:10.1016/j.mpmed.2014.08.008 · Cited by 3
Management of unruptured intracranial aneurysms
(2014) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000019 · Cited by 3
Direct Oral Anticoagulation Versus Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves: a Retrospective, Real-World Cohort Study
Eikelboom, R., Whitlock, R. P., Sibilio, S., Nguyen, F., Perez, R., Weitz, J. I., & Belley‐Côté, E. P. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07381-5 · Cited by 3
Management of Intracranial Hemorrhage in the Setting of Mechanical Heart Valve Replacement Therapy
Khan, S., Syed, F., & Toma, M. (2023) · Applied Mechanics · doi:10.3390/applmech4020033 · Cited by 3
New pharmacotherapeutic options for oral anticoagulant treatment in atrial fibrillation patients aged 65 and older: factor XIa inhibitors and beyond
Santostasi, G., Denas, G., & Pengo, V. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2219391 · Cited by 3
The new era of anticoagulation: factor XI and XII inhibitors
Prisco, D., Mattioli, I., Caterina, R. D., & Bettiol, A. (2023) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2023.76 · Cited by 3
Direct Oral Anticoagulant Use Early After Cardiac Surgery: A Retrospective Cohort Study
Wu, J.-J., Jiang, J., Ye, J., Turgeon, R. D., & Wang, E. H. Z. (2023) · CJC Open · doi:10.1016/j.cjco.2023.09.017 · Cited by 3
“7,8 9-11 The only RCT found conducted to date on DOACs early after cardiac surgery was limited to 56 participants and was not powered to detect a difference in bleeding events or stroke.”
Background
Management of ischaemic stroke survivors in primary care setting: the road to holistic care
Ozdemir, H., Sagris, D., Abdul‐Rahim, A. H., Lip, G. Y. H., & Shantsila, E. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03445-y · Cited by 8
Factor XI/XIa Inhibitors: A New Approach to Anticoagulation
Whiteson, H. Z., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000624 · Cited by 3
Anticoagulant Prescribing Patterns in New-Onset Atrial Fibrillation After Cardiac Surgery
Krahn, K. M., Koshman, S. L., Wang, T., Chen, J., Bungard, T. J., Zhou, J. S., Omar, M. A., & Cowley, E. C. (2023) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2023.11.031 · Cited by 3
Treatment options for isolated aortic valve insufficiency: a review
Argaw, S. T., Azizgolshani, N., Blitzer, D., Takayama, H., George, I., & Pirelli, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1381102 · Cited by 3
Oral anticoagulant treatment in atrial fibrillation: the AFIRMA real-world study using natural language processing and machine learning
Cosı́n-Sales, J., Anguita, M., Suárez, C., Arias-Cabrales, C., Martínez-Sánchez, L. M., Arumí, D., & de Cabo, S. F. (2024) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2024.06.002 · Cited by 3
Apixaban plasma levels in patients with HeartMate 3 support
Edom, C. J. V., Cools, B., Droogné, W., Jacobs, S., Puyvelde, J. V., Vlasselaers, D., Vanassche, T., & Meyns, B. P. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.11.003 · Cited by 3
Major Bleeding and Thromboembolic Events with the On-X Mechanical Aortic Valve Prosthesis: A SWEDEHEART Study
Lu, R., Dismorr, M., Dalén, M., Glaser, N., & Sartipy, U. (2025) · Interdisciplinary CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivaf182 · Cited by 3
Vascular Engineering of Blood Coagulation
Goto, S. (2016) · Springer eBooks · doi:10.1007/978-4-431-54801-0_11 · Cited by 3
Defibrillation Testing During ICD Implantation – Should we or Should we Not?
Hayase, J. H., & Boyle, N. G. (2017) · Journal of Atrial Fibrillation · doi:10.4022/jafib.1508 · Cited by 3
A response to critics: weakening the ethical distinction between euthanasia, palliative opioid use and palliative sedation
Riisfeldt, T. D. (2019) · Journal of Medical Ethics · doi:10.1136/medethics-2019-105906 · Cited by 3
“7 By the same token, although opioids and sedatives are safe in the setting of an elective total hip replacement, they may not be safe in the entirely different context of a frail patient with metastatic lung cancer in a hospice, and we simply do not have good evidence to know this one way or the…”
ACOD frente a AVK en pacientes con fibrilación auricular y recambio valvular aórtico por bioprótesis
García, V. E., Lozano, D. S., Miñambres, Á. A., Entem, F. R., Enríquez, S. G., Villa, S. C., Quevedo, V. T., Crespo, C. J., Palacio-Portilla, E. J., Hernández, J. M. D. L. T., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2020.12.001 · Cited by 3
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry
Hess, P. L., GOSCH, K. L., Jani, S. M., Varosy, P. D., Bradley, S. M., Maddox, T. M., Ho, P. M., & Virani, S. S. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.04.017 · Cited by 3
Antithrombotika und Antihämorrhagika
Wille, H. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_17 · Cited by 3
Management of atrial fibrillation: What is new in the 2014 ACC/AHA/HRS guideline?
Rajagopalan, B., & Curtis, A. B. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022495 · Cited by 3
Management of atrial fibrillation: recommendations from NICE
Lim, W. Y., & Khan, F. Z. (2015) · British Journal of Hospital Medicine · doi:10.12968/hmed.2015.76.7.c108 · Cited by 3
Should we offer a bioprosthetic valve to women of child-bearing age who need valve replacement?
Hirsch, R. (2014) · Interventional Cardiology · doi:10.2217/ica.14.37 · Cited by 3
Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic
da Costa, M. A. C., Krum, L. K., Geraldino, J. D. S., Schafranski, M. D., Gomes, R. Z., & Reis, E. S. D. S. (2016) · Brazilian Journal of Cardiovascular Surgery · doi:10.5935/1678-9741.20160055 · Cited by 3
Az új orális antikoagulánsokkal történő kezelés laboratóriumi vonatkozásai
Bereczky, Z., Oláh, Z., Ajzner, É., & Kappelmayer, J. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30928 · Cited by 3
Arteriolar vs. valvular thrombosis: Pick your evil!
Berry, A., Degheim, G., & Saba, S. E. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0175-3 · Cited by 3
Outpatient Oral Anticoagulant Therapy
Ansell, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00037-6 · Cited by 3
Stroke Prevention with Non-Vitamin K Oral Anticoagulants: For Most, but Not for All!
Steffel, J. (2019) · Cardiology · doi:10.1159/000501586 · Cited by 3
“A Tale of Two Cities”: Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants
Palmiero, G., Melillo, E., & Rubino, A. S. (2019) · Medicina · doi:10.3390/medicina55080437 · Cited by 3
Successful Long‐term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve
Wang, X., Mathew, C., Korapati, S., & Bathini, V. G. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2361 · Cited by 3
Antiphospholipid syndrome and challenges with direct oral anticoagulants
Booth, S. W., Burton, K., Hunt, B. J., & Desborough, M. (2020) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0080 · Cited by 3
Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease
Gusdon, A. M., Farrokh, S., & Grotta, J. C. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726331 · Cited by 4
Recurrent embolisms despite adequate anticoagulant therapy in a patient with prosthetic heart valves and atrial fibrillation: a case report
Marschall, A., Torres, D. J. R., Liñares, A. R., & Sánchez, D. M. (2021) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytab263 · Cited by 3
“Since the use of novel oral anticoagulants (NOACs) increased rates of thromboembolic events and bleeding complications in patients with mechanical heart valves, NOACs are currently not recommended for these patients.(1,2) Thus, anticoagulation with an VKA agent was the only alternative for our patient.”
Background
Therapie der Aortenklappenstenose
Widder, J. D., & Bauersachs, J. K. (2014) · Der Internist · doi:10.1007/s00108-014-3555-1 · Cited by 3
Operating in the Dark
Kiernan, M. S., & Katz, J. N. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003141 · Cited by 3
Dabigatran versus warfarin in patients with mechanical heart valves: comment
Christensen, T. D., & Larsen, T. B. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12497 · Cited by 3
Antithrombotic Therapy Following CABG
Alexander, J. H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.049 · Cited by 3
High Rates of Off-label Prescribing and the Urgent Need for a Randomized Clinical Trial
Návar, A. M., & Mehran, R. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0612 · Cited by 3
The impact of acute diarrhea on the coagulation status of patients with vitamin K antagonists
Schweinfurth, J., Bauer, A., Bauer, F., Seibert, F. S., Rohn, B., Seidel, M., Bertram, S., Stervbo, U., Babel, N., & Westhoff, T. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-91316-x · Cited by 2
Late Clinical Valve Thrombosis After Transcatheter Aortic Valve Replacement Despite Non-Vitamin K Anticoagulant
Carmeliet, T., Vermeersch, P. H. M. J., & Prihadi, E. A. (2021) · JACC Case Reports · doi:10.1016/j.jaccas.2021.06.012 · Cited by 2
“As the use of DOAC in mechanical heart valves is associated with increased risk of thromboembolic and bleeding complications (6), several observational studies also observe a trend to increased ischemic events with DOAC after TAVR (7).”
Background
Utility of a pharmacist-managed Anticoagulation Program in patients with congenital heart disease
O’Neil, M. J., Garr, B., Faircloth, J. M., Ciambarella, J. A., Lubert, A. M., Nelson, N. L., & Cooper, D. S. (2023) · Cardiology in the Young · doi:10.1017/s1047951123003268 · Cited by 2
Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? – A Literature Review
Gerfer, S., Wahlers, T., & Kuhn, E. W. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00371-8 · Cited by 2
Vascular vertigo and dizziness: managing and treating outpatients
Neto, A. C. L., & Bittar, R. S. M. (2024) · Brazilian Journal of Otorhinolaryngology · doi:10.1016/j.bjorl.2024.101453 · Cited by 2
Efficacy and safety of mechanical pulmonary valve replacement: a comprehensive systematic review and meta-analysis
Rafati, A., Rashedi, S., Pasebani, Y., Vahedinejad, M., Ghoshouni, H., Toloueitabar, Y., Mousavizadeh, M., Saedi, S., Jalali, A., Khajali, Z., et al. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03471-1 · Cited by 2
New horizons in the pharmacological management of venous thromboembolism
Verstraete, A., Thillo, Q. V., Vanassche, T., & Verhamme, P. B. (2025) · HemaSphere · doi:10.1002/hem3.70143 · Cited by 2
In Silico and In Vitro Studies of Potential Novel Vitamin K Epoxide Reductase (VKOR) Inhibitors Suggest an Updated Structure–Activity Relationship
Mortel, S. L. R., Macalino, S. J. Y., Wang, M., & Tie, J. (2025) · ACS Omega · doi:10.1021/acsomega.5c01116 · Cited by 3
Management of Chronic Antithrombotic Medication in Total Joint Arthroplasty: A Primer for the Orthopaedic Surgeon
von Treuheim, T. D. P., Ruff, G. L., Shanaa, J., Schwarzkopf, R. M., & Aggarwal, V. K. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.09.020 · Cited by 2
Sex differences in outcomes of vitamin K antagonist treatment in patients with a mechanical heart valve: a Dutch population-based cohort study
Kempers, E. K., Visser, C., Seelig, J., Chen, Q., Adriaansen, H. J., Beinema, M. J., ten Cate‐Hoek, A. J., Faber, L. M., Dronkers, C. E. A., Nierman, M. C., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.09.010 · Cited by 2
Anticoagulation Strategies for Left Ventricular Thrombus After Myocardial Infarction: A Review
Folman, A., Toukan, N., Kobo, O. M., Roguin, A., & Barel, M. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227982 · Cited by 2
“The RE-ALIGN trial of dabigatran in mechanical prosthetic valves was terminated early due to excess thromboembolic and bleeding events [25].”
Rationale for and design of the REsolution of LEft VENTricular thrombus (RELEVENT) Trial
Hillis, G. S., Walker, J. A., Gilbert, T., Budgeon, C. A., French, J. K., Selvanayagam, J. B., Dhakshinamurthy, V. A., Troughton, R. W., Moragues, J., Ihdayhid, A. R., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107301 · Cited by 2
Anticoagulation Therapy in Advanced Chronic Kidney Disease: Balancing Bleeding and Thromboembolic Risk
Suliman, I. L., Tuta, L. A., Panà, C., Panculescu, F. G., Alexandru, A., Fasie, D., Cîmpineanu, B., Popescu, S., Enache, F.-D., Nitu, R. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062577 · Cited by 2
“For apixaban: The administration of a 5 mg twice-daily dose in patients who met the standard criteria for dose reduction to 2.5 mg twice daily (based on age, weight, and serum creatinine levels) or in those undergoing chronic hemodialysis [28,29].”
Influential
Thrombin generation and the pharmacodynamics of parenteral anticoagulants
Shaw, J. R., Maier, C. L., Hardy, M. J., Mullier, F., Douxfils, J., Tanaka, K. A., Rocca, B., Cate, H. T., Kim, P. Y., Carrier, M., et al. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100135 · Cited by 2
Developments and risk analysis in anticoagulation
Khan, N. (2015) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2015.10.2.66 · Cited by 2
Prosthetic thrombosis and pregnancy on warfarin: Debate on mechanical mitral valve replacement in sub-Saharan Africa based on a case report
Arioli, F., D'Arbela, P. G., Aloi, F., Nsubuga, M. M., Grimaldi, A., & Ammirati, E. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.162 · Cited by 2
Mechanical mitral valve prosthesis: Should the INR be above 2 when aspirin is added to the oral anticoagulant?
Fawzy, A., Ali, H., & Elanwar, M. (2017) · Journal of the Egyptian Society of Cardio-Thoracic Surgery · doi:10.1016/j.jescts.2017.06.001 · Cited by 1
Identifying Clinical Predictors of Switching From Direct Oral Anticoagulants to Warfarin
Rollins, A., Hanigan, S., Pogue, K. T., Renner, E., Barnes, G. D., & Dorsch, M. P. (2019) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x19831287 · Cited by 2
Neurologic complications of nonrheumatic valvular heart disease
Cruz‐Flores, S. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819814-8.00003-2 · Cited by 2
Impact of an oral anticoagulation self-monitoring and self-management program in patients with mechanical heart valve prosthesis
Blanch, P., Freixa‐Pamias, R., Gambau, M., Lafuente, R., & Basile, L. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0215 · Cited by 2
Peculiarity of clinical course of postpericardiotomy syndrome in different methods of surgery and postoperative antithrombotic therapy
Mangileva, T. A., Kazantseva, O. A., & Karaseva, I. V. (2021) · Kardiologiia · doi:10.18087/cardio.2021.4.n1374 · Cited by 2
Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valves—A Systematic Review and Meta-analysis
Ruzieh, M., Wolbrette, D. L., & Naccarelli, G. V. (2021) · Journal of Innovations in Cardiac Rhythm Management · doi:10.19102/icrm.2021.121202 · Cited by 2
Development and validation of a bleeding risk prediction score for patients with mitral valve stenosis and atrial fibrillation or mechanical heart valves receiving long‐term warfarin therapy
Phetroong, S., Nathisuwan, S., Chindavijak, B., Phrommintikul, A., Sapoo, U., Sookananchai, B., Priksri, W., & Lip, G. Y. H. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15540 · Cited by 2
Emergências Relacionadas à Doença Valvar Cardíaca: Uma Revisão Abrangente da Abordagem Inicial no Departamento de Emergência
Accorsi, T. A. D., Paixão, M. R., de Souza, J. L., Gaz, M. V. B., Cardoso, R. G., Kohler, K. F., Lima, K. D. A., & Tarasoutchi, F. (2023) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20220707 · Cited by 5
Stroke prevention strategies for cardiac surgery: a systematic review and meta‐analysis of randomized controlled trials
Fong, K. Y., Yeo, S., Luo, H., Kofidis, T., Teoh, K., & Kang, G. S. (2024) · ANZ Journal of Surgery · doi:10.1111/ans.18947 · Cited by 2
Comparison of Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban in Patients With Valvular Atrial Fibrillation: A Network Meta-Analysis of Randomized-Control Trials and Observational Studies
Huma, H., Rawat, A., Kaur, M., Jha, O., Gill, F. S., Moqattash, M., Wei, C. R., & Allahwala, D. (2024) · Cureus · doi:10.7759/cureus.57656 · Cited by 2
Antithrombotic therapy after heart valve surgery: contemporary practice in the UK
Laskar, N., Bayliss, C. D., Kirmani, B. H., Chambers, J. B., Maier, R. H., Briffa, N. P., Cartwright, N., Kendall, S. W. H., Shah, B. N., & Akowuah, E. (2024) · Interdisciplinary CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivae089 · Cited by 2
Changes in Time in Therapeutic Range Within a Warfarin Anticoagulation Clinic Following Introduction of Direct Oral Anticoagulants
Samuel, P., Cassidy, K., Lazarevskiy, P., & Cope, R. J. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241256779 · Cited by 2
Support for Thrombolytic Therapy for Acute Stroke Patients on Direct Oral Anticoagulants: Mortality and Bleeding Complications.
Koscumb, P., Murphy, L. R., Talbott, M. M., Nuti, S. A., Golovko, G., Shaltoni, H. M., & Jehle, D. V. K. (2024) · PubMed Central · doi:10.5811/westjem.18063 · Cited by 2
Predictors of Device-Related Thrombus After Left Atrial Appendage Occlusion: TED-F2 Score
Jiwani, S., Morgan, E., Baghdadi, S., Smith, R., Tabak, C., Parikh, R., Bajaj, M., Enders, R., Uhlich, C., Baer, J., et al. (2024) · CJC Open · doi:10.1016/j.cjco.2024.05.015 · Cited by 2
“24,25 The existing literature on using direct OACs for post-LAAO anticoagulation protocols suggests that this strategy is effective, similar to warfarin use, although trials with direct head-to-head comparisons are not available.”
Factors Correlated with Anticoagulation Choice in Primary Care Patients with Atrial Fibrillation and High Stroke Risk
Weng, C., Kuo, H., Aho, B., McGookin, E. D., & Chan, P. A. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08871-y · Cited by 2
Clinical Outcomes and Risk Factors of Heart Transplantation Patients Experiencing Gastrointestinal Bleeding
Li, W., Zhang, C., Zhou, X., Xu, Q., Wang, K., Lin, R., Shi, J., & Dong, N. (2024) · Biomedicines · doi:10.3390/biomedicines12081845 · Cited by 2
“Our nomogram predictive model incorporating its independent risk factors, including age, preoperative warfarin, postoperative CRRT and postoperative nasogastric tubes, showed favorable predictive value.”
Method
Contemporary Multi-modality Imaging of Prosthetic Aortic Valves
Abadie, B. Q., & Wang, T. K. M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25339 · Cited by 2
Apixaban Anticoagulation in HeartMate 3 Left Ventricular Assist Device: A Meta-Analysis of Randomized Controlled Trials
Cherbi, M., Vandenbriele, C., Baudry, G., & Delmas, C. (2025) · ASAIO Journal · doi:10.1097/mat.0000000000002385 · Cited by 2
Machine Learning Application for Bleeding Risk Prediction in Patients with Atrial Fibrillation Treated with Oral Anticoagulation
Lerman, T. T., Tiosano, S., Beigel, R., Cohen, M. S., Kornowski, R., Munitz, R., Nace, D. A., Hassan, S., Scandrett, K. G., Forman, D. E., et al. (2025) · Acta Haematologica · doi:10.1159/000546663 · Cited by 3
Direct oral anticoagulants in left ventricular assist devices: Where are we now?
Arroyo, L. B., Gallone, G., Baldetti, L., Gramegna, M., Castelein, T., Dierckx, R., Fiorelli, F., Gorog, D. A., Galiatsou, E., Lyster, H. S., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.08.025 · Cited by 2
2025 Thai guideline for the diagnosis and management of atrial fibrillation
Ngarmukos, T., Methavigul, K., Rungpradubvong, V., Apiyasawat, S., Wongcharoen, W., Pumprueg, S., Boonyapisit, W., Suwanagool, A., Chantrarat, T., Makarawate, P., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0028 · Cited by 2
Does dabigatran interfere with intraablation heparinization?
Sairaku, A., Nakano, Y., & Kihara, Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.06.026 · Cited by 2
Renal function in patients with mechanical prosthetic valves
Çanga, Y., Güvenç, T. S., Çalık, A. N., Karataş, M. B., Akdeniz, E., Yüksel, G., & Emre, A. (2018) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1350-z · Cited by 2
Diagnosis and Management of Rare Case of Mesenteric Hematoma Rupture after Transcatheter Aortic Valve Replacement (TAVR): A Case Report and Review of the Literature
Abbasi, D., Vanhook, J. E., Salartash, K., & Levite, H. A. (2018) · Case Reports in Vascular Medicine · doi:10.1155/2018/6273538 · Cited by 2
Les traitements anticoagulants oraux chez les personnes âgées : faut-il encore prescrire des antivitamines K ?
Lafuente‐Lafuente, C., Oasi, C., & Belmin, J. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.11.010 · Cited by 2
Anticoagulants and Antiplatelet Agents in Pregnancy
Drebes, A. B., Gates, C., & Maguire, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-15120-5_2 · Cited by 2
Extrapolation des données physiopathologiques à la pratique clinique : à propos du dabigatran utilisé hors AMM
Molinier, A., Acket, B., Bourrel, R., Lavezzi, O.-F., Montastruc, J., & Bagheri, H. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2013.11.009 · Cited by 2
Common Questions in Anticoagulation Management in Atrial Fibrillation
Gallego, P., Roldán, V., & Lip, G. Y. H. (2014) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2013.10.005 · Cited by 2
Dabigatran etexilate for venous thromboembolism: a safety evaluation
Brown, R., Lip, G. Y. H., & Gallego, P. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.895321 · Cited by 2
Mitral valve prosthesis choice for patients aged 65 years and over in the UK. Are the guidelines being followed and does it matter?
Dimarakis, I., Grant, S. W., Hickey, G. L., Patel, R. L., Livesey, S. A., Moat, N. E., Wells, F. C., & Bridgewater, B. (2013) · Heart · doi:10.1136/heartjnl-2013-304783 · Cited by 2
General Medical Considerations for the Wilderness Adventurer: Medical Conditions That May Worsen With or Present Challenges to Coping With Wilderness Exposure
Cushing, T. A., Roberts, W. O., Hackett, P. H., Dexter, W. W., Brent, J. S., Young, C. C., Fudge, J. R., Hawkins, S. C., DeLoughery, T. G., Thomas, B. J., et al. (2015) · Wilderness and Environmental Medicine · doi:10.1016/j.wem.2015.09.007 · Cited by 2
Plasma Vitamin K1 Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case–Control Study
Cafolla, A., Gentili, A., Cafolla, C., Pérez‐Fernández, V., Baldacci, E., Pasqualetti, D., Demasi, B., & Curini, R. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0169-0 · Cited by 2
Fibrinolytic Treatment after Transient Ischaemic Attack Caused by Prosthetic Mitral Valve Thrombosis
Koban, C., Neuß, M., Tambor, G., Hölschermann, F., & Butter, C. (2016) · Case Reports in Cardiology · doi:10.1155/2016/6809263 · Cited by 2
A Clinically Oriented Review of the Landmark Clinical Trials Comparing Warfarin and Aspirin to Novel Oral Anticoagulants in Atrial Fibrillation
Rahman, A. M. (2019) · doi:10.17303/jcvm.2014.2.402 · Cited by 2

Authors: Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F.
Affiliations: Hamilton Health Sciences (CA)
Boehringer Ingelheim (Germany) (DE)
Duke University (US)
Erasmus MC (NL)
Heart Hospital Baylor Plano (US)
Boehringer Ingelheim (United Kingdom) (GB)
Boehringer Ingelheim (United States) (US)
Boehringer Ingelheim (France) (FR)
KU Leuven (BE)
ORCID: Eikelboom, John W.
Connolly, Stuart J.
Brueckmann, Martina
Granger, Christopher B.
Kappetein, Arie P.
Mack, Michael J.
Blatchford, Jon
Guiver, Kelly
Khder, Yasser
Lobmeyer, Maximilian T.
Voigt, Jens-Uwe
Simoons, Maarten L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-09-26
Volume: 369
Issue: 13
Pages: 1206-1214
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1300615
OpenAlex: W2016875529
Cited by: 1,506
References: 27
Citations by year: 2026: 52 · 2025: 84 · 2024: 111 · 2023: 95 · 2022: 102 · 2021: 140 · 2020: 130 · 2019: 113 · 2018: 119 · 2017: 128 · 2016: 116 · 2015: 131 · 2014: 147 · 2013: 36
FWCI: 97.35
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: dabigatran, warfarin, mechanical heart valves, direct thrombin inhibitors, anticoagulation, thromboembolism, bleeding complications, pericardial bleeding, stroke, aortic valve replacement, mitral valve replacement, dose adjustment
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Female, Heart Valve Prosthesis, Hemorrhage, Humans, Male, Middle Aged, Thromboembolism, Warfarin, beta-Alanine, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks